Skip to content
Biodatica
Start free

The Lymphoma Academic Research Organisation

Liège

OncologyCAR-TPhase II
Compare Sign in to watch

What changed

Phase II trial registered: Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

3mo agoTrial registeredMar 27, 2026Source filing (opens the source filing in a new tab)

Momentum

71no change

Momentum 71 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Aug 20, 2025

    Peripheral T Cells Lymphoma (PTCL) · RECRUITING · sponsor: The Lymphoma Academic Research Organisation · A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

    ClinicalTrials.gov · NCT07018752 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Mar 10, 2021

    B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent · ACTIVE_NOT_RECRUITING · sponsor: The Lymphoma Academic Research Organisation · Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

    ClinicalTrials.gov · NCT04531046 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources